Market Segmentation:
- By Product Type
- Gene Therapies
- Antisense Oligonucleotides
- Small Molecule Drugs
- Others (Symptomatic Treatments, etc.)
- By Route of Administration
- Oral
- Parenteral
- Others (Intrathecal, etc.)
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others (Direct Tenders, etc.)
- By End User
- Hospitals
- Specialty Clinics
- Home Healthcare
- Others (Research Institutes, etc.)
- By Mechanism of Action
- Huntingtin Lowering Therapies
- Neuroprotective Therapies
- Symptomatic Therapies
- Others
- By Stage of Disease
- Early-Stage
- Mid-Stage
- Late-Stage
- By Regions
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Frequently Asked Questions
The Huntington's Disease Treatment Market had an estimated market size of US$ 1.2 billion in 2023.
Increasing prevalence of the disease, lack of curative treatments, rising healthcare expenditure globally, government initiatives and funding, advancements in gene therapy research, biomarker and diagnostic improvements, personalized medicine and precision therapy approaches, and stem cell therapy developments.
High treatment costs involved, stringent regulatory approval processes, lack of disease awareness, limited patient pool globally.
The gene therapy segment is the leading component segment in the Huntington's Disease Treatment Market, offering potential curative treatments through gene editing technologies.
Roche, Ionis Pharmaceuticals, Wave Life Sciences, UniQure, Sangamo Therapeutics, Pfizer, Teva Pharmaceutical Industries, Novartis, Valeant Pharmaceuticals, Allergan.
The Huntington's Disease Treatment Market is projected to grow at a CAGR of 17.8% from 2024 to 2031 and reach a market size of US$ 4.4 billion by 2031. North America is expected to lead the Huntington's Disease Treatment Market.
Increasing prevalence of the disease, lack of curative treatments, rising healthcare expenditure globally, government initiatives and funding, advancements in gene therapy research, and biomarker and diagnostic improvements.